ライフサイエンスコーパス: age-related macular degeneration

1 ) mainly focused on diabetic retinopathy and age-related macular degeneration.

2 s to prioritise likely causal biomarkers for age-related macular degeneration.

3 valent cause of vision loss in patients with age-related macular degeneration.

4 ing drug target for diabetic retinopathy and age-related macular degeneration.

5 cal validation for patients with neovascular age-related macular degeneration.

6 the eye from many retinal diseases, such as age-related macular degeneration.

7 /100 for millions of patients suffering from age-related macular degeneration.

8 to irreversible blindness in the setting of age-related macular degeneration.

9 ology of proliferative vitreoretinopathy and age-related macular degeneration.

10 ent injury and choroidal vascular disease in age-related macular degeneration.

11 d improved visual outcomes for patients with age-related macular degeneration.

12 s with common eye diseases like glaucoma and age-related macular degeneration.

13 can resolve ambiguity about cone survival in age-related macular degeneration.

14 sFLT01 in patients with advanced neovascular age-related macular degeneration.

15 g proliferative diabetic retinopathy and wet age-related macular degeneration.

16 ch as retinitis pigmentosa (RP) and atrophic age-related macular degeneration.

17 rders as proliferative vitreoretinopathy and age-related macular degeneration.

18 the protective effect of FHR-1 deficiency in age-related macular degeneration.

19 for therapeutics and diagnostics directed at age-related macular degeneration.

20 sthesis in patients affected by dry atrophic age-related macular degeneration.

21 rapeutic target in patients with neovascular age-related macular degeneration.

22 aphic atrophy (GA) secondary to nonexudative age-related macular degeneration.

23 erived RPE cells to treat conditions such as age-related macular degeneration.

24 nibizumab retreatment schemes in neovascular age-related macular degeneration.

25 ative diseases like retinitis pigmentosa and age-related macular degeneration.

26 typical hemolytic uremic syndrome (aHUS) and age-related macular degeneration.

27 ot only in retinitis pigmentosa, but also in age-related macular degeneration.

28 ong women, with no sex difference related to age-related macular degeneration (0.91 [0.70-1.14]).

29 ractive error (61.3%), cataract (13.2%), and age-related macular degeneration (10.3%).

30 in direct or indirect costs associated with age-related macular degeneration ($17 379.41-$657 406.55

31 Age-related macular degeneration 4 included neovascular

32 .6 million [18.2 million to 109.6 million]), age-related macular degeneration (8.4 million [0.9 milli

33 ent of the abnormal deposits associated with age-related macular degeneration, Alzheimer's disease, a

34 Age related macular degeneration (AMD) is the most commo

35 Age-related macular degeneration (AMD) - the leading cau

36 Age-related macular degeneration (AMD) affects millions

37 Age-related macular degeneration (AMD) affects the retin

38 H (FH) predisposes individuals to acquiring age-related macular degeneration (AMD) after aging.

39 bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare be

40 23 (60%) had geographic atrophy secondary to age-related macular degeneration (AMD) and 2 eyes (5%) h

41 ix of 15 eyes were diagnosed with coincident age-related macular degeneration (AMD) and 2 with myopic

42 nts were 55 to 90 years with GA secondary to age-related macular degeneration (AMD) and best-correcte

43 HTRA1) are associated with increased risk of age-related macular degeneration (AMD) and disease progr

44 ociated with many ocular diseases, including age-related macular degeneration (AMD) and glaucoma.

45 f depression and anxiety among subjects with age-related macular degeneration (AMD) and its associati

46 ator, are associated with the development of age-related macular degeneration (AMD) and other complem

47 Age-related macular degeneration (AMD) and related macul

48 tion between susceptible genetic variants to age-related macular degeneration (AMD) and response to a

49 hy (OCT) images of patients with neovascular age-related macular degeneration (AMD) and to demonstrat

50 o late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide re

51 ence of ethnicity on the association between age-related macular degeneration (AMD) and vision-specif

52 Current prediction models for advanced age-related macular degeneration (AMD) are based on a re

53 ateral large drusen and without nGA nor late age-related macular degeneration (AMD) at baseline were

54 arkers for the progression of nonneovascular age-related macular degeneration (AMD) attributed to ant

55 en was tested in eyes with large drusen from age-related macular degeneration (AMD) before and after

56 imed to identify metabolites associated with age-related macular degeneration (AMD) by performing the

57 a reported decline in the risk of developing age-related macular degeneration (AMD) continued for peo

58 the RNFL thinning may be secondary to active age-related macular degeneration (AMD) disease progressi

59 Use of CSIs to assess visual function in age-related macular degeneration (AMD) found CSI guided

60 tervention to slow or prevent progression of age-related macular degeneration (AMD) from its early st

61 Offspring of parent(s) with age-related macular degeneration (AMD) have a 45% lifeti

62 ctor H (CFH) gene and their association with age-related macular degeneration (AMD) have been describ

63 Several prediction models for progression of age-related macular degeneration (AMD) have been develop

64 ss in elderly population, worldwide cases of age-related macular degeneration (AMD) have seen a drama

65 rmine the 6-year incidence of early and late age-related macular degeneration (AMD) in a Singaporean

66 secutive naive eyes diagnosed with exudative age-related macular degeneration (AMD) in comparison wit

67 ce to a Mediterranean diet and prevalence of age-related macular degeneration (AMD) in countries rang

68 evaluate the incidence of intermediate-stage age-related macular degeneration (AMD) in patients with

69 The status of age-related macular degeneration (AMD) in the fellow eye

70 Age-related macular degeneration (AMD) is a chronic eye

71 Age-related macular degeneration (AMD) is a chronic, mul

72 Age-related macular degeneration (AMD) is a common multi

73 Age-related Macular Degeneration (AMD) is a complex eye

74 rowth factor (VEGF) treatment of neovascular age-related macular degeneration (AMD) is a highly effec

75 Age-related macular degeneration (AMD) is a leading caus

76 Age-related macular degeneration (AMD) is a leading caus

77 Age-related macular degeneration (AMD) is a major cause

78 Age-related macular degeneration (AMD) is a multifactori

79 Age-related macular degeneration (AMD) is a progressive

80 Age-related macular degeneration (AMD) is a progressive

81 Early age-related macular degeneration (AMD) is characterized

82 ne of the strongest susceptibility genes for age-related macular degeneration (AMD) is complement fac

83 Age-related macular degeneration (AMD) is highly prevale

84 patients should eat to reduce their risk of age-related macular degeneration (AMD) is still unclear.

85 Age-related macular degeneration (AMD) is the leading ca

86 Age-related macular degeneration (AMD) is the leading ca

87 Age-related macular degeneration (AMD) is the leading ca

88 Age-related macular degeneration (AMD) is the most commo

89 Age-related macular degeneration (AMD) is the most commo

90 Age-related macular degeneration (AMD) is the primary ca

91 To evaluate the impact of age-related macular degeneration (AMD) on short out-loud

92 oting the pathological neovascularization in age-related macular degeneration (AMD) or diabetic macul

93 at-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control

94 tive was to assess whether older adults with age-related macular degeneration (AMD) or glaucoma perfo

95 ll population but are strongly implicated in age-related macular degeneration (AMD) pathogenesis, a s

96 scin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis.

97 type 1 neovascularization (NV) in eyes with age-related macular degeneration (AMD) receiving anti-va

98 RNAs (miRs) in diabetic retinopathy (DR) and age-related macular degeneration (AMD) remains unclear.

99 cted loss-of-function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD

100 en genetic predictors of lipid fractions and age-related macular degeneration (AMD) risk.

101 stionnaire (LLQ) in patients with a range of age-related macular degeneration (AMD) severity are asso

102 Age-related macular degeneration (AMD) showed moderate a

103 ountered most often in eyes with neovascular age-related macular degeneration (AMD) that had type 1 m

104 ographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to pro

105 visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially

106 plasma metabolomic profile of patients with age-related macular degeneration (AMD) using mass spectr

107 he retinal pigment epithelium (RPE) cells in age-related macular degeneration (AMD) using polarimetry

108 tural OCT images from eyes with nonexudative age-related macular degeneration (AMD) were graded for t

109 d be part of standard care for patients with age-related macular degeneration (AMD) who are being con

110 y 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD) with bilateral la

111 genetic variants at 34 loci contributing to age-related macular degeneration (AMD)(1-3).

112 RD shows striking phenotypic similarities to age-related macular degeneration (AMD), a common and gen

113 Age-related macular degeneration (AMD), a leading cause

114 The two most common genetic contributors to age-related macular degeneration (AMD), a leading cause

115 Age-related macular degeneration (AMD), a leading contri

116 phagocytes are implicated in the etiology of age-related macular degeneration (AMD), a major cause of

117 Age-related macular degeneration (AMD), a multifactorial

118 and is a factor contributing to the risk for age-related macular degeneration (AMD), a retinal diseas

119 eases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), are among the le

120 moting choroidal neovascularization (CNV) in age-related macular degeneration (AMD), but central ques

121 Other diseases, such as age-related macular degeneration (AMD), develop late in

122 ine the health literacy of 225 patients with age-related macular degeneration (AMD), diabetic macular

123 ht-threatening ocular comorbidity other than age-related macular degeneration (AMD), diabetic retinop

124 exposure to PPS and to drusen, nonexudative age-related macular degeneration (AMD), exudative AMD, h

125 cross a diverse range of diseases, including age-related macular degeneration (AMD), glaucoma and ref

126 Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause

127 To prevent irreversible vision loss in age-related macular degeneration (AMD), it is critical t

128 identified genetic variants associated with age-related macular degeneration (AMD), one of the leadi

129 al impairment in patients suffering from wet age-related macular degeneration (AMD), particularly whe

130 is, rhegmatogenous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative di

131 In age-related macular degeneration (AMD), rare variants in

132 In assessing the severity of age-related macular degeneration (AMD), the Age-Related

133 ithelium (RPE) underlies the pathogenesis of age-related macular degeneration (AMD), the leading caus

134 rods has been implicated in the pathology of age-related macular degeneration (AMD), the most common

135 at 34 genetic loci that are associated with age-related macular degeneration (AMD), the most common

136 e choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of reti

137 SFD closely resembles age-related macular degeneration (AMD), which is the lea

138 ctively recruited patients with intermediate age-related macular degeneration (AMD), without other vi

139 st arose at 80 years of age or later, showed age-related macular degeneration (AMD)-like fundus chang

140 inal diseases, diabetic retinopathy (DR) and age-related macular degeneration (AMD).

141 trates progressive degeneration in aging and age-related macular degeneration (AMD).

142 or confirmed to have glaucoma and exudative age-related macular degeneration (AMD).

143 subsequent ION in patients with neovascular age-related macular degeneration (AMD).

144 hat prevent or delay development to advanced age-related macular degeneration (AMD).

145 ea and enlargement measurements in eyes with age-related macular degeneration (AMD).

146 eyes and from eyes with drusen secondary to age-related macular degeneration (AMD).

147 ensity lipoproteins (HDLs) are implicated in age-related macular degeneration (AMD).

148 allmarks in the induction and progression of age-related macular degeneration (AMD).

149 ase, retinitis pigmentosa (RP), and atrophic age-related macular degeneration (AMD).

150 e type 3 MNV in their post-nascent stage and age-related macular degeneration (AMD).

151 NV) is the major cause of vision loss in wet age-related macular degeneration (AMD).

152 al OCT images from images from patients with Age-related Macular Degeneration (AMD).

153 ophy based on OCT findings in the setting of age-related macular degeneration (AMD).

154 hway, are altered in patients with exudative age-related macular degeneration (AMD).

155 e and inflammatory retinal disorders such as age-related macular degeneration (AMD).

156 systemic inflammation increases the risk of age-related macular degeneration (AMD).

157 ceptor alterations in eyes with intermediate age-related macular degeneration (AMD).

158 ed high-fat intakes with a high incidence of age-related macular degeneration (AMD).

159 lop drusenoid lesions which are hallmarks of age-related macular degeneration (AMD).

160 s supposed to contribute the pathogenesis of age-related macular degeneration (AMD).

161 ing inflammatory marker associated with late age-related macular degeneration (AMD).

162 and the intermediate and advanced stages of age-related macular degeneration (AMD).

163 izumab with aflibercept to treat neovascular age-related macular degeneration (AMD).

164 l study visits and graded centrally for late age-related macular degeneration (AMD).

165 be one of the first cell classes affected by age-related macular degeneration (AMD).

166 t geographic atrophy (GA) onset secondary to age-related macular degeneration (AMD).

167 nd at a younger age than in individuals with age-related macular degeneration (AMD).

168 rce-optical coherence tomography (SS-OCT) in age-related macular degeneration (AMD).

169 s a hallmark early feature of nonneovascular age-related macular degeneration (AMD).

170 (MNV) is supposed to be a rare condition in age-related macular degeneration (AMD).

171 more complex diseases of the eye, including age-related macular degeneration (AMD).

172 ical studies link Periodontal disease(PD) to age-related macular degeneration (AMD).

173 eat colorectal and breast cancers as well as age-related macular degeneration (AMD).

174 y may play a key role in the pathogenesis of age-related macular degeneration (AMD).

175 a hallmark of the human wet, or neovascular age-related macular degeneration (AMD).

176 n cognition (Alzheimer's disease) and sight (age-related macular degeneration [AMD]).

177 ms regulating the normal and diseased state (age related macular degeneration, AMD) in the retina.

178 ents aged 50 years or older with neovascular age-related macular degeneration and a baseline best-cor

179 nt B cystatin C, a recessive risk factor for age-related macular degeneration and Alzheimer's disease

180 prevalence during treatment for neovascular age-related macular degeneration and are associated with

181 To report patients with age-related macular degeneration and atypical central re

182 (FH; official name, CFH) are associated with age-related macular degeneration and atypical hemolytic

183 other retinal degenerative diseases such as age-related macular degeneration and diabetic retinopath

184 od vessels is common in eye diseases such as age-related macular degeneration and diabetic retinopath

185 Neovascular age-related macular degeneration and diabetic retinopath

186 tial therapies for retinal diseases, such as age-related macular degeneration and inherited retinal d

187 isk SNPs with age-related phenotypes such as age-related macular degeneration and longevity.

188 se vision loss in many eye diseases, such as age-related macular degeneration and macular telangiecta

189 that recombinant I62-CFH (protective against age-related macular degeneration) and V62-CFH functioned

190 ic macular edema, 32 (25.8%) had neovascular age-related macular degeneration, and 32 (25.8%) had oth

191 lar pathologic features, including glaucoma, age-related macular degeneration, and epiretinal membran

192 conditions, including diabetic retinopathy, age-related macular degeneration, and past cataract surg

193 on (CNV) in body donor eyes with neovascular age-related macular degeneration are limited by the time

194 d in the retinal pigment epithelium (RPE) of age-related macular degeneration (ARMD) patients and the

195 is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillari

196 sregulated in various pathologies, including age-related macular degeneration, arthritis, and cancer.

197 Eyes with age-related macular degeneration-associated choroidal ne

198 ses individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic ure

199 Age-related macular degeneration automated detection was

200 itreous bevacizumab injections for exudative age-related macular degeneration between January 1, 2009

201 treatment of ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic re

202 Geographic atrophy is a blinding form of age-related macular degeneration characterized by retina

203 tely one third of diabetic macular edema and age-related macular degeneration clinical trials registe

204 se taking metformin were less likely to have age-related macular degeneration compared with those not

205 ensus Definition for Atrophy Associated with Age-Related Macular Degeneration-defined atrophy.

206 liferative diabetic retinopathy, neovascular age-related macular degeneration, diabetic macular edema

207 e anterior (dry eye syndrome) and posterior (age-related macular degeneration, diabetic retinopathy a

208 ctors contribute to vascular inflammation in age-related macular degeneration, diabetic retinopathy,

209 , after adjusting for age, gender, glaucoma, age-related macular degeneration, diabetic retinopathy,

210 na to developing blinding conditions such as age-related macular degeneration, diabetic retinopathy.

211 Progression to exudative 'wet' age-related macular degeneration (exAMD) is a major caus

212 Age-related macular degeneration features from SD OCT, I

213 Compared to exudative age-related macular degeneration fewer injections are ne

214 Inherited retinal dystrophies and late-stage age-related macular degeneration, for which treatments r

215 Neovascular age-related macular degeneration-free survival.

216 subjects and 6 eyes with drusen secondary to age-related macular degeneration from 6 subjects were an

217 study (GWAS) published by the International Age-related Macular Degeneration Genomics consortium of

218 of European ancestry from the International Age-related Macular Degeneration Genomics Consortium.

219 Ophthalmic diseases, such as age-related macular degeneration, glaucoma, and diabetic

220 vision impairment) and a high prevalence of age-related macular degeneration (>14% of blindness) as

221 phic atrophy (nGA) in eyes with intermediate age-related macular degeneration (iAMD).

222 , active choroidal neovascularization due to age-related macular degeneration in the study eye were r

223 Age related macular degeneration is the leading cause of

224 Age-related macular degeneration is a leading cause of v

225 Age-related macular degeneration is a major cause of vis

226 Early stages of geographic atrophy (GA) age-related macular degeneration is characterised by the

227 Geographic atrophy (GA) secondary to age-related macular degeneration is considered a single

228 phic atrophy (GA), a progressive dry form of age-related macular degeneration is elusive and there is

229 Neovascular age-related macular degeneration is one of the leading c

230 The other, age-related macular degeneration, is the most common for

231 hat critically contributes to vision loss in age-related macular degeneration, is unclear.

232 The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-mo

233 tings of inherited retinal degenerations and age-related macular degeneration.Literature discussed he

234 Age-related macular degeneration may be more than a "mac

235 visual outcomes in patients with neovascular age-related macular degeneration (nAMD) during anti-vasc

236 onthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat a

237 Describing the natural course of neovascular age-related macular degeneration (nAMD) is essential in

238 acuity (VA) change in real-world neovascular age-related macular degeneration (nAMD) patients.

239 Treatment-naive eyes with neovascular age-related macular degeneration (nAMD) tracked by the F

240 real-world data of patients with neovascular age-related macular degeneration (nAMD) treated with int

241 cular occlusion in patients with neovascular age-related macular degeneration (nAMD) treated with int

242 raphic atrophy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ran

243 re identified from a registry of neovascular age-related macular degeneration (nAMD) treatment outcom

244 visual outcomes in patients with neovascular age-related macular degeneration (nAMD) who received ant

245 nts treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macula

246 entral role in the management of neovascular age-related macular degeneration (nAMD), diabetic retina

247 data regarding the treatment of neovascular age-related macular degeneration (nAMD).

248 wth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD).

249 retinal sensitivity in eyes with neovascular age-related macular degeneration (nAMD).

250 Francisco, CA) in patients with neovascular age-related macular degeneration (nAMD).

251 olucizumab versus aflibercept in neovascular age-related macular degeneration (nAMD).

252 mab monotherapy in patients with neovascular age-related macular degeneration (nAMD).

253 .5 mg for eligible patients with neovascular age-related macular degeneration (nAMD).

254 e main goal for the treatment of neovascular age-related macular degeneration (nAMD).

255 th approved for the treatment of neovascular age-related macular degeneration (nAMD).

256 ase activity among patients with neovascular age-related macular degeneration (nAMD).

257 tor (VEGF) injection therapy for neovascular age-related macular degeneration (nAMD).

258 etinal vein occlusion (RVO), and neovascular-age related macular degeneration (nvAMD).

259 phy (OCT) in guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research

260 eat-and-extend (TAE) regimen for neovascular age-related macular degeneration (NVAMD).

261 nd aflibercept monotherapies for neovascular age-related macular degeneration (NVAMD).

262 ensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT, it is unclear w

263 the retinal pigment epithelium in eyes with age-related macular degeneration or central serous chori

264 h factor agents for treatment of neovascular age-related macular degeneration or diabetic macular ede

265 When a patient with neovascular age-related macular degeneration or diabetic macular ede

266 retinal diseases such as Stargardt disease, age-related macular degeneration or retinitis pigmentosa

267 aps significantly with sets found by GWAS of age-related macular degeneration (P=1.4 x 10(-12)), ulce

268 ogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal h

269 (2017) show that iPSC-derived RPE cells from age-related macular degeneration patients express increa

270 tor (VEGF) treatment patterns in neovascular age-related macular degeneration patients in 2012-2015.

271 An exemplary search for patients with age-related macular degeneration, performed cataract sur

272 treal aflibercept injections for neovascular age-related macular degeneration presented 4 weeks after

273 Retinal dystrophies and age-related macular degeneration related to photorecepto

274 Loss of photoreceptors in atrophic age-related macular degeneration results in severe visua

275 We evaluated 37 eyes with age-related macular degeneration that had serous PED.

276 In age-related macular degeneration, the retinal pigment ep

277 hy of prematurity, diabetic retinopathy, and age-related macular degeneration, threaten the visual he

278 million (17.9 million to 124.1 million), by age-related macular degeneration to 8.8 million (0.8 mil

279 to managing diseases, including stroke, AD, age-related macular degeneration, traumatic brain injury

280 er 2 years of treatment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

281 w-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

282 ective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

283 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials.

284 dicare fee schedule, and CATT (Comparison of Age-Related Macular Degeneration Treatments) study and V

285 l diseases including an epiretinal membrane, age-related macular degeneration, vitreomacular traction

286 growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire

287 isite, international registry of neovascular age-related macular degeneration was analyzed with an in

288 Age-related macular degeneration was assessed using the

289 Age-related macular degeneration was attributed as the m

290 Age-related macular degeneration was diagnosed and grade

291 phy (OCT) volume scans of 1094 patients with age-related macular degeneration, we generated a vocabul

292 me and generic multivitamin formulations for age-related macular degeneration were obtained.

293 R, retinopathy of prematurity (ROP), and wet age-related macular degeneration (wet AMD) have been fou

294 Roclatan for glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for

295 Similarities to OCT features in age-related macular degeneration, where mitochondrial dy

296 Patients with neovascular age-related macular degeneration who demonstrated a subo

297 ncluding atrophy outcome(s) in patients with age-related macular degeneration who received anti-VEGF

298 year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in th

299 We applied our method to an in-depth GWAS of age-related macular degeneration with 33,976 individuals

300 sculopathy (PCV) is a variant of neovascular age-related macular degeneration with distinct phenotype